News for hackers. Stuff that matters.
Re:mRNA's next challenge: Will it work as a drug? by _greim_ on Friday December 18, 2020 @02:04PM (#25470628)
Okay, layman's speculation: Given we can co-opt cells to manufacture proteins for us like this, and given we can predict what shape of protein an mRNA strand would produce, does this open up all sorts of potential in medical treatments? Tear it apart, HN.
Re:mRNA's next challenge: Will it work as a drug? by kens on Friday December 18, 2020 @02:13PM (#25470734)
I'm not sure I understand the question, as that's the point of the article. Clinical trials are currently testing mRNA to produce proteins to treat cystic fibrosis, heart failure and various obscure conditions. There are various problems, such as ensuring the the protein is created in the right cells, requiring repeated doses so the protein is created over a long time, handling side effects, and increasing the amount of protein created. So mRNA isn't an easy solution.
Re:mRNA's next challenge: Will it work as a drug? by lucaswoj on Friday December 18, 2020 @02:09PM (#25470699)
Re:mRNA's next challenge: Will it work as a drug? by arrosenberg on Friday December 18, 2020 @02:16PM (#25470769)
Yeah, that's basically what the article discusses. It will be easier for non-targeted treatments that can circulate the whole body. This tech (by itself) doesn't really solve the issue of delivering site-specific medication.
Re:mRNA's next challenge: Will it work as a drug? by flobosg on Friday December 18, 2020 @02:12PM (#25470726)
> given we can predict what shape of protein an mRNA strand would produce

For therapeutic proteins you usually work the other way around: You design the shape and try to get a sequence that folds as intended. In other words, the inverse folding problem.

Re:mRNA's next challenge: Will it work as a drug? by elcritch on Friday December 18, 2020 @05:44PM (#25473000)
The parent is referring to the recent DeepFold success in predicting protein shapes from DNA/RNA, which means it appears to have solved the inverse folding problem for many proteins (modulo more exotic protein “features”). I haven’t read the article (yet), but presumably being able to go from desired protein shape to plausible nucleotide sequences to mRNA to produce them would enable a lot of drugs to be developed that were cost/resource prohibitive previously. Presuming you can get access to DeepFold and the compute time to run it on semi-random sequences until you get matching shapes.
Re:mRNA's next challenge: Will it work as a drug? by flobosg on Friday December 18, 2020 @06:13PM (#25473261)
> it appears to have solved the inverse folding problem for many proteins

While this is true, DeepFold’s algorithm is only applicable to extant proteins having enough evolutionary information, which is arguably a small fraction of the theoretical sequence space. Fortunately, machine-learning approaches for de novo protein design are being actively developed as we speak.

Re:mRNA's next challenge: Will it work as a drug? by elcritch on Friday December 18, 2020 @07:13PM (#25473679)
> While this is true, DeepFold’s algorithm is only applicable to extant proteins having enough evolutionary information,

Didn't the challenge include predicting previously unseen/unsolved proteins? Based on that, I would wager that what DeepFold learned is an evolutionary "language" that maps out a large useful subset of the entire possibility space. Natural evolution tends build upon previous successes so it seems probable evolution has mapped out a fairly useful "language" of patterns for useful protein shapes. Especially given only a portion of the shape is critical to function for many proteins.

But agreed, de novo protein design based on DeepFold's successes probably will outperform a naive approach by orders of magnitude. But why wait if even a naive approach is already orders of magnitude better than current methods?

Either way, I'm excited to see who comes up with the first custom protein(s) to catalyze industrial processes! Get some yeast/bacteria to mass produce a protein based alternative to platinum catalyzer's for fuel cells using an active site with organically available (and cheap) metals. Design half of it to stick to a polymer so it coats nicely. Bam, no more trying to get some weird polymer/perovskite with the right properties. Not sure mRNA is needed at that point versus CRISPR, but maybe it's more effective.

Re:mRNA's next challenge: Will it work as a drug? by flobosg on Friday December 18, 2020 @07:49PM (#25473915)
> Didn't the challenge include predicting previously unseen/unsolved proteins?

All protein sequences in the competition lacked a published solved structure, but they had enough effective (remotely) homologous sequences to predict coevolution-derived interresidue distances and contacts. All those sequences were already present in databases and therefore within the known protein universe.

> Based on that, I would wager that what DeepFold learned is an evolutionary "language" that maps out a large useful subset of the entire possibility space.

This might be true, depending on how “foldable” the unexplored space is. A reverse DeepFold would give some clues on that.

> Natural evolution tends build upon previous successes so it seems probable evolution has mapped out a fairly useful "language" of patterns for useful protein shapes

This is already known. The structural and functional diversity we see in existing proteins originated from a relatively limited repertoire of conserved protein domain folds, or even subdomain-sized fragments in some cases.

> Either way, I'm excited to see who comes up with the first custom protein(s) to catalyze industrial processes!

Same here! Especially since the de novo design of enzymes has been progressing slowly but steadily.

Re:mRNA's next challenge: Will it work as a drug? by elcritch on Saturday December 19, 2020 @01:14AM (#25475512)
> but they had enough effective (remotely) homologous sequences to predict coevolution-derived interresidue distances and contacts.

Ah, I see what you're saying a bit better. Makes more sense to how the the possible "design" space for novel proteins could be limited. Designing novel active sites could be especially tricky, more than it'd seem at first glance. A folded structure that'd effectively transfer electrons from one target species to another in a catalyzer protein could likely be outside the explored "vocabulary" of extant proteins as it'd require specialized pathways and precise positioning. Chlorophyll is pretty unchanged in evolution as I understand it.Thanks, interesting background! I'll keep an eye out for the de novo design algorithms.

Re:mRNA's next challenge: Will it work as a drug? by hirenj on Saturday December 19, 2020 @05:30AM (#25476525)
Yes, and no. The principle is there, but it is important to understand that each cell type is essentially a specialist factory to produce proteins, and the drug may be produced best when you get exactly the right factory to produce the protein (I’m thinking about PTMs). If your body is flooded by inferior product from the wrong factories, the effect of the superior product may be inhibited of diluted.

That said, I can imagine once we figure out how to deliver the mRNA to precisely the right targets, this would be a lot easier (eg engineering receptor ligands onto the mRNA lipid delivery particles).

Re:mRNA's next challenge: Will it work as a drug? by tboyd47 on Friday December 18, 2020 @02:19PM (#25470806)
On face value, it sounds less risky than the standard vaccine development route, which may involve introducing immortalized (i.e. cancerous) cells or artificially stimulating an immune response with known toxins (adjuvants).

I still have questions about the mRNA vaccine concept. Maybe some well-informed HNer can shed light?

1. If the goal is to get the desired protein inside the patient's body, why is injecting mRNA that produces the protein more effective than simply introducing the protein itself?

2. How does the patient's immune system know to treat this protein as unwanted if it's being produced by the body's own cells?

3. How do vaccine developers avoid creating an over-active immune response in the patient (i.e. an allergy)?

Re:mRNA's next challenge: Will it work as a drug? by BurningFrog on Friday December 18, 2020 @02:45PM (#25471069)
> 2. How does the patient's immune system know to treat this protein as unwanted if it's being produced by the body's own cells

The immune system can't know who produced a certain molecule.

Re:mRNA's next challenge: Will it work as a drug? by therein on Friday December 18, 2020 @02:41PM (#25471025)
I have been asking the very same questions, especially the (2).

So far, nobody has been able to provide a satisfying answer.

Re:mRNA's next challenge: Will it work as a drug? by fabian2k on Friday December 18, 2020 @02:50PM (#25471125)
The simplistic answer is that the immune system tries out new antigen-detecting cells in a safe environment before letting them run around with a loaded gun. Any cell that activates in that safe environment is destroyed, as it recognized one of your own antigens.

The other mechanism is that the immune system doesn't react only to foreign antigens, there also needs to be some general activation of the immune system in that area for a real response.

The full answer is that this is really, really complex like pretty much everything involving the immune system. And auto-immune diseases indicate that the immune system doesn't always get this right.

Re:mRNA's next challenge: Will it work as a drug? by tboyd47 on Friday December 18, 2020 @03:08PM (#25471304)
How is that general activation achieved in the case of this mRNA vaccine and the others that will surely follow?
Re:mRNA's next challenge: Will it work as a drug? by fabian2k on Friday December 18, 2020 @03:16PM (#25471377)
RNA itself is suspicious because it's a major component of many viruses. So some kinds of RNA will activate the innate immune system strongly.
Re:mRNA's next challenge: Will it work as a drug? by tboyd47 on Friday December 18, 2020 @04:12PM (#25472096)
That's really interesting and confirmed with some light searching. Thanks!
Re:mRNA's next challenge: Will it work as a drug? by rolph on Friday December 18, 2020 @03:38PM (#25471633)
there is a system homologous to machine learning 2factor authentication.

in very loose terms both keys must be presented while the immune system is in training, the instances where protiens are expressed with out cell surface recognition molecules in proximity are invalid thus foriegn, and memory immunity to this "failed login" is maintained. when both factors [protien plus recognition] are present constituitively over the course of development the immune response is squelched.

this is known as central tolerance.

https://en.wikipedia.org/wiki/Central_tolerance

Re:mRNA's next challenge: Will it work as a drug? by gostsamo on Friday December 18, 2020 @02:52PM (#25471141)
1. A single rna can produce multiple times the protein, because it is like the proverb about giving someone fish and teaching them fishing.

2. Someone already said, but a protein has no marker saying "local produce". It is either allowed or not and the body reacts or not when detecting it.

3. They hope. Measure the dosage and adjust. As it was reported, some people getting the vaccine have an allergic reaction, but hopefully it will be rare and under control. So far there are only a few cases reported.

Re:mRNA's next challenge: Will it work as a drug? by fabian2k on Friday December 18, 2020 @02:30PM (#25470918)
Adjuvants are not toxic, they're simply known to enhance the immune system response (so they are something that indicates danger to the immune system). The immune system is incredibly dangerous and destructive, and you really don't want to trigger it without reason. So injecting something unknown might not be enough to get the immune system fully alarmed, that's why some vaccines add adjuvants to produce a stronger response. RNA can be an adjuvant by itself, as it's also a typical component of viruses and the immune system reacts to that.

So the trick really is to design the RNA and the delivery system so that it produces an immune response of the right magnitude. Too weak and it doesn't work, too strong and it's harmful.

Antibodies that bind to your own proteins are filtered in an earlier stage in antibody production. Real viral proteins are also produced by your own cells, so that is never a factor by which you could distinguish friend from foe.

Re:mRNA's next challenge: Will it work as a drug? by tboyd47 on Tuesday December 29, 2020 @10:36AM (#25570715)
Is aluminum not toxic?
Re:mRNA's next challenge: Will it work as a drug? by raducu on Friday December 18, 2020 @02:35PM (#25470963)
1. I guess for smaller batches it is easier to develop the mRNA. Otherwise, we would have monoclonal antibodies and not a vaccine(the vaccine has other benefits, it trains the T-cells and the B cells remain dormant even after no abtibodies are detected in the blood).

2. The imune system knows all your protein already, t cells are evolved in the thymus gland, if they attack anything "self", they get destriyed.

Re:mRNA's next challenge: Will it work as a drug? by gus_massa on Friday December 18, 2020 @02:36PM (#25470973)
> which may involve introducing immortalized (i.e. cancerous) cells

Which one? I don't remember any vaccine that injects immortalized cells.

Re:mRNA's next challenge: Will it work as a drug? by tboyd47 on Friday December 18, 2020 @02:45PM (#25471068)
Feel free to correct if I'm misinterpreting: https://en.wikipedia.org/wiki/Use_of_fetal_tissue_in_vaccine...
Re:mRNA's next challenge: Will it work as a drug? by rolph on Friday December 18, 2020 @03:27PM (#25471499)
the vaccine doesnt contain fetal cells, in the case you are providing the vaccine is an attenuated virus approach.

the cells are used to manufacture quantities of the virus in an extremely weakened form. This gives a chance for the immune systemto mount a response before the pathogen initiates systemic disease response.

the cells in question are not freshly harvested from a foetus, the progenitor cells are harvested and kept in continual culture for use. the reason immortalized cells are used is to escape the "expiry date" of a normal cell.

>>Some vaccines currently available were developed using cell strains cultured from two fetuses aborted for other purposes in the 1960s.[6]<<

i lifted this link from the wiki page provided:

https://en.wikipedia.org/wiki/Immortalised_cell_line

Re:mRNA's next challenge: Will it work as a drug? by tboyd47 on Friday December 18, 2020 @04:22PM (#25472220)
Thanks.
Re:mRNA's next challenge: Will it work as a drug? by theophrastus on Friday December 18, 2020 @02:29PM (#25470897)
A layman's speculation followed by a layman's (at least in terms of immunology) question: introduce a novel mRNA, cells produce novel protein, it is presented to the immune system as something to foment a defense again: vaccine. But the article talks about using this mechanism to replace a functional copy of a genetically missing enzyme. How is it assured that this will assume the opposite goal and not become another target for the immune system to guard against?
Re:mRNA's next challenge: Will it work as a drug? by ryanianian on Friday December 18, 2020 @02:32PM (#25470941)
On the opposite side: how do we effectively convince people this new type of vaccine is safe long-term? I'm not a biology person, so I trust the biology people when they say it's safe, but many don't.

My intuition is that many cancers can start when proteins are mis-copied, and mRNA therapy seems to rely on copying to work very reliably. Does introduced mRNA increase the risk or impacts of mis-copying?

Is there an ELI5 intuition for why mRNA therapy is safe and won't lead to cells becoming cancerous?

Re:mRNA's next challenge: Will it work as a drug? by delecti on Friday December 18, 2020 @02:48PM (#25471096)
Cancers start when DNA is mis-copied. Typically DNA is copied to RNA, which is then used to generate protein, and there isn't usually a mechanism for that RNA to go back a step to become DNA again. I don't want to say it's impossible, or that there's no conceivable negative effects, but cancer seems like an implausible result from mRNA therapy.
Re:mRNA's next challenge: Will it work as a drug? by dharma1 on Friday December 18, 2020 @03:03PM (#25471252)
Not related to mRNA therapy, but retroviruses use reverse transcriptase to attach their RNA to the DNA of the host cell
Re:mRNA's next challenge: Will it work as a drug? by delecti on Friday December 18, 2020 @03:42PM (#25471692)
Thank you, that's a good addition. I knew it didn't happen with mRNA, but also knew that there was _a_ route from RNA to DNA, though I couldn't remember what. That's why I hedged my statement with "usually".
Re:mRNA's next challenge: Will it work as a drug? by raducu on Friday December 18, 2020 @02:37PM (#25470985)
I don't think mRNA spreads from cell to cell, the mRNA enters a limited number of cells and those cells start producing certain proteins the mRNA tells them to.
Re:mRNA's next challenge: Will it work as a drug? by mamon on Friday December 18, 2020 @03:15PM (#25471362)
> how do we effectively convince people this new type of vaccine is safe long-term?

Same as always: do a long-term clinical trial and look for any side effects.

Re:mRNA's next challenge: Will it work as a drug? by sveiss on Friday December 18, 2020 @03:27PM (#25471509)
I'll state upfront that I'm not a biologist, but here's my attempt at the explanation.

The ELI5 version:

Think of the cell as a factory for proteins. The blueprints for all of the different kinds of proteins it can produce are encoded in DNA and stored in the foreman's office. When the cell wants to make a particular protein, the foreman copies the instructions from the blueprint onto slips of paper (mRNA), and sends them to the assembly line workers. This type of copying happens all the time, and is pretty reliable -- and even if it's not, the end result is just some wasted time and a junk part. The blueprints are unaffected. mRNA vaccines sneak some unauthorized instructions to the workers, who then run a ghost shift to produce the protein we want to cause an immune response to.

When we need to create a second factory, we need to photocopy all the blueprints for the new cell. This uses a totally different process (a photocopier assembled specifically for the job of copying whole blueprints onto more blueprint paper, and not the work-order slips sent to the assembly line). The photocopier is pretty reliable too, but occasionally it introduces artifacts, and eventually, enough of these errors can build up to create mistakes in the blueprints. The blueprints have instructions on how to deal with errors in a new factory (by blowing it up), but if enough of those failsafe instructions are obscured by copier artifacts, you now have a potentially cancerous cell.

The foreman's office doesn't usually make changes to the blueprints based on work order slips. It's possible with a special copy machine -- this is how HIV works, by sneaking that machine in -- but without a work order slip to blueprint copier, it doesn't matter how many fake work order slips we pass into the cell. They will only affect the production line, not the foreman's office.

The more detailed, and almost certainly wrong-in-the-details version:

There are three types of encoding for genetic material: in DNA, in RNA, and in proteins.

In order for the information encoded in genetic information to be active in a biological system, it has to be expressed as a protein -- a physical manifestation with binding sites and the ability to interact with other molecules. Ribosomes, a component of the cell, do the "assembly" part of transferring genetic information to a protein. This is called "translation".

DNA is the long-term storage of the information eventually expressed as proteins -- it's a collection of templates in long term storage. So there has to be a process to get information from the long-term storage of DNA, in the nucleus of the cell, to the ribosomes elsewhere in the cell.

Messenger RNA is the intermediary molecule which carries the genetic information from the DNA to the ribosomes. It's produced in the nucleus of the cell by a mechanism called "transcription", which copies a subset of a DNA molecule into a complementary RNA molecule encoding the same information. The DNA double-helix is "unzipped", a complementary RNA strand is assembled, and the double-helix reforms. The mRNA can then be transported to the ribosomes.

mRNA is a useful vaccine mechanism, because we're co-opting a late stage of the cell's protein production pipeline. We don't have to assemble the target protein by hand and figure out how to modify it make it stable for distribution -- a task that would need to be repeated for each protein we wanted to make. Instead, we can figure out how to synthesis mRNA, and we don't need to worry about either synthesis or stability for the end protein product.

When we talk about cancer and mis-copying, this is at a much earlier stage in the pipeline. When a cell splits into two cells through mitosis, we don't want a subset of the protein templates in the cell's genetic material; we want a complete copy. This is a separate biological pipeline, which involves the cell building up a mechanism to do the copying, dissolving the membrane of the nucleus, and ultimately producing and collating copies of all the DNA from the nucleus. This is an entirely separate process, and messenger RNA isn't involved at all.

There is a route for information to travel from RNA back to DNA, and this is the mechanism retroviruses use, and HIV is the most famous example. A complete retrovirus particle includes reverse transcriptase, an enzyme which allows them to transfer information from RNA back to DNA. This is the reverse of the normal DNA -> RNA pattern described above, hence the name _retro_virus. Without that enzyme or something like it, there isn't a pathway to convert RNA back to DNA, and human cells don't normally express an enzyme which has this function.

Re:mRNA's next challenge: Will it work as a drug? by strbean on Friday December 18, 2020 @02:07PM (#25470660)
Seems to be working well so far for COVID vaccines. We're about to witness a very large scale test though.